Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BTAI Stock Forecast 2026-2027
$1.16
Current Price
$36.13M
Market Cap
Buy 3
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to BTAI Price Targets
+3,175.9%
To High Target of $38.00
+632.8%
To Median Target of $8.50
-13.8%
To Low Target of $1.00
BTAI Price Momentum
+8.4%
1 Week Change
+1.8%
1 Month Change
-31.4%
1 Year Change
-27.5%
Year-to-Date Change
-85.6%
From 52W High of $8.08
+14.9%
From 52W Low of $1.01
📊 TOP ANALYST CALLS
Did BTAI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bioxcel is one of their latest high-conviction picks.
Latest BTAI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, BTAI has a bullish consensus with a median price target of $8.50 (ranging from $1.00 to $38.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $1.16, the median forecast implies a 632.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTAI Analyst Ratings
3
Buy
0
Hold
1
Sell
BTAI Price Target Range
Low
$1.00
Average
$8.50
High
$38.00
Current: $1.16
Latest BTAI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTAI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Mar 17, 2026 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 12, 2025 | Mizuho | Neutral | Maintains | $N/A | |
| Aug 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 15, 2025 | LUCID CAPITAL MARKETS | Buy | Reiterates | $N/A | |
| Jun 23, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 19, 2025 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Jan 30, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 7, 2025 | B of A Securities | Underperform | Downgrade | $N/A | |
| Jan 6, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 21, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 30, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 9, 2024 | UBS | Neutral | Maintains | $N/A | |
| Aug 8, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 27, 2024 | Canaccord Genuity | Buy | Maintains | $N/A |
BioXcel Therapeutics, Inc. (BTAI) Competitors
The following stocks are similar to Bioxcel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BioXcel Therapeutics, Inc. (BTAI) Financial Data
BioXcel Therapeutics, Inc. has a market capitalization of $36.13M with a P/E ratio of -0.2x. The company generates $680,000 in trailing twelve-month revenue with a 74.5% profit margin.
Revenue growth is +22.6% quarter-over-quarter, while maintaining an operating margin of -4,962.6% and return on equity of +73.2%.
Valuation Metrics
Market Cap
$36.13M
Enterprise Value
$118.31M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
51.8x
Growth & Margins
Revenue Growth (YoY)
+22.6%
Gross Margin
-37.4%
Operating Margin
-4,962.6%
Net Margin
+74.5%
EPS Growth
+22.6%
Financial Health
Cash/Price Ratio
+47.9%
Current Ratio
0.6x
Debt/Equity
-1.0x
ROE
+73.2%
ROA
-86.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BioXcel Therapeutics, Inc. (BTAI) Business Model
About BioXcel Therapeutics, Inc.
What They Do
Develops AI-driven medicines in neuroscience and oncology.
Business Model
The company generates revenue through the development and commercialization of innovative therapeutics, specifically focusing on treatments for mental health disorders and cancer. Its lead product, IGALMI, is already approved for market, while several investigational drugs are in various stages of clinical trials, potentially leading to future sales.
Additional Information
Incorporated in 2017 and based in New Haven, Connecticut, BioXcel Therapeutics collaborates with prestigious academic institutions to enhance its drug discovery processes. The company is positioned as a clinical-stage biopharmaceutical entity within the competitive U.S. market, with a strong emphasis on addressing unmet medical needs.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
37
CEO
Dr. Vimal D. Mehta Ph.D.
Country
United States
IPO Year
2018
Website
www.bioxceltherapeutics.comBioXcel Therapeutics, Inc. (BTAI) Latest News & Analysis
Latest News
Quick Summary
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings prospects and potential for stock price appreciation.
Why It Matters
BioXcel Therapeutics' upgrade to a Zacks Rank #2 signals increased investor confidence, potentially boosting demand and stock prices in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BioXcel Therapeutics (Nasdaq: BTAI) presented positive Phase 3 SERENITY trial data for BXCL501, aimed at treating agitation in bipolar disorders and schizophrenia, at the ASCP Annual Meeting.
Why It Matters
Positive trial results for BXCL501 enhance BioXcel Therapeutics' growth potential, indicating advances in treatment options for mental health, which can drive stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
1 month ago
Quick Summary
BioXcel Therapeutics' sNDA for IGALMI® in outpatient use was accepted by the FDA, with a PDUFA date set for Nov. 14, 2026. The company is exploring strategic options to enhance shareholder value.
Why It Matters
FDA acceptance of IGALMI® for at-home use boosts BioXcel's growth potential, impacting revenue forecasts. Strategic evaluations signal proactive management aimed at enhancing shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BioXcel Therapeutics reported a quarterly loss of $0.54 per share, better than the expected loss of $0.59, and an improvement from a loss of $1.50 per share a year earlier.
Why It Matters
BioXcel's smaller-than-expected loss signals potential operational improvements, possibly boosting investor confidence and impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
BioXcel Therapeutics (BTAI) is expected to report earnings that may exceed forecasts due to a favorable combination of key factors. Investors should prepare for this upcoming report.
Why It Matters
BioXcel Therapeutics' potential earnings beat could positively impact its stock price, signaling financial health and growth prospects, which may attract more investors and boost market confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BioXcel Therapeutics, Inc. (BTAI) outlined its commercial launch strategy and market potential for IGALMI in at-home settings.
Why It Matters
BioXcel's strategy for IGALMI's at-home launch highlights potential revenue growth and market expansion, impacting future earnings and stock performance for BTAI.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About BTAI Stock
What is BioXcel Therapeutics, Inc.'s (BTAI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, BioXcel Therapeutics, Inc. (BTAI) has a median price target of $8.50. The highest price target is $38.00 and the lowest is $1.00.
Is BTAI stock a good investment in 2026?
According to current analyst ratings, BTAI has 3 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTAI stock?
Wall Street analysts predict BTAI stock could reach $8.50 in the next 12 months. This represents a 632.8% increase from the current price of $1.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BioXcel Therapeutics, Inc.'s business model?
The company generates revenue through the development and commercialization of innovative therapeutics, specifically focusing on treatments for mental health disorders and cancer. Its lead product, IGALMI, is already approved for market, while several investigational drugs are in various stages of clinical trials, potentially leading to future sales.
What is the highest forecasted price for BTAI BioXcel Therapeutics, Inc.?
The highest price target for BTAI is $38.00 from at , which represents a 3,175.9% increase from the current price of $1.16.
What is the lowest forecasted price for BTAI BioXcel Therapeutics, Inc.?
The lowest price target for BTAI is $1.00 from at , which represents a -13.8% decrease from the current price of $1.16.
What is the overall BTAI consensus from analysts for BioXcel Therapeutics, Inc.?
The overall analyst consensus for BTAI is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $8.50.
How accurate are BTAI stock price projections?
Stock price projections, including those for BioXcel Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 2:28 AM UTC